Tuesday, September 22, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutidecopdpioglitazoneglp-1 receptor

Semaglutide cuts MUC5AC mucin in cell and mouse airway model

Researchers compared six GLP-1 receptor agonists and two PPAR-gamma agonists against pyocyanin-driven mucus hypersecretion, with effects blocked by Exendin(9-39).

PR
By Priya Raman · Science Reporter
Sep 6 20:00 ETSource: Frontiers in immunology

The wire

  1. 01In Frontiers in Immunology, semaglutide and pioglitazone were most effective at lowering MUC5AC expression and reactive oxygen species in bronchial cells and C57BL/6 mice exposed to Pseudomonas aeruginosa pyocyanin.
  2. 02The authors frame repurposed semaglutide as a possible adjunct in COPD, a use well outside current metabolic indications clinicians see.
  3. 03Work is confined to cell cultures and a mouse chronic bronchitis model; no human data support an airway indication.

From the source

Semaglutide and pioglitazone restore airway mucosal homeostasis by resolving Pseudomonas aeruginosa pyocyanin-induced mucus hypersecretion, ciliostasis, and type 2 airway inflammation

Frontiers in immunology · 2026 · Wu C, Kulkarni NA, Lew SQ et al.

Read at pubmed.ncbi.nlm.nih.gov